Analyst Price Targets — RAPP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 9:40 am | Tiago Fauth | Raymond James | $66.00 | $34.12 | TheFly | Rapport Therapeutics initiated with a Strong Buy at Raymond James |
| March 9, 2026 1:49 pm | Kambiz Yazdi | BTIG | $47.00 | $29.97 | StreetInsider | BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough" |
| February 2, 2026 10:58 am | Benjamin Burnett | Wells Fargo | $43.00 | $26.61 | TheFly | Rapport Therapeutics initiated with an Overweight at Wells Fargo |
| December 19, 2025 10:19 am | — | Wells Fargo | $51.00 | $29.64 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Rapport Therapeutics (RAPP) |
| December 9, 2025 11:09 am | Douglas Tsao | H.C. Wainwright | $40.00 | $30.16 | TheFly | Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright |
| September 16, 2025 10:11 am | Joon Lee | Truist Financial | $44.00 | $24.85 | TheFly | Rapport Therapeutics initiated with a Buy at Truist |
| July 2, 2024 4:51 am | Andrew Tsai | Jefferies | $35.00 | $25.44 | TheFly | Rapport Therapeutics initiated with a Buy at Jefferies |
| July 2, 2024 2:47 am | Paul Matteis | Stifel Nicolaus | $35.00 | $25.44 | StreetInsider | Stifel Starts Rapport Therapeutics (RAPP) at Buy |
Latest News for RAPP
A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mise à disposition du Rapport financier annuel 2025 de Crédit Mutuel Home Loan SFH Crédit Mutuel Home Loan SFH informe que ce document est à la disposition du public sur le site de l'émetteur, à l'adresse suivante : https://www.creditmutuel-homeloansfh.eu/en/covered-bonds/documentation/investor-documents.html Ce…
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong
LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. The collaboration combines Neuphonic's ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by…
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset…
Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RAPP.
U.S. House Trading
No House trades found for RAPP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.